Description
Dapotime (Dapoxetine) 60 mg
Dapotime 60 mg is a branded oral tablet product containing dapoxetine, a short-acting selective serotonin reuptake inhibitor (SSRI). Dapoxetine has been developed specifically for the treatment of premature ejaculation in adult men in jurisdictions where it is authorised for this use.
Active Ingredient and Medicine Class
The verified active ingredient is dapoxetine, usually supplied as dapoxetine hydrochloride. It belongs to the SSRI class. Unlike longer-acting antidepressant SSRIs, dapoxetine has a rapid onset and a short duration of action, which is why it has been studied as an on-demand treatment rather than a continuous daily medicine.
Established Medical Uses
The established indication is treatment of premature ejaculation in adult men. Official European product information describes use in men aged 18 to 64 years. This medicine is not established as a treatment for erectile dysfunction, low libido, infertility, or general sexual performance concerns.
How It Works
Dapoxetine increases serotonin signalling by inhibiting serotonin reuptake. Serotonin is involved in the neural control of ejaculation, and increasing its availability is thought to delay ejaculation and improve perceived control. The medicine’s short pharmacokinetic profile supports intermittent, as-needed use in approved settings.
Important Safety Information
Dapoxetine has clinically important safety limitations. It should not be used with monoamine oxidase inhibitors, thioridazine, other serotonergic antidepressants, lithium, linezolid, tramadol, tryptophan, St John’s wort, and several migraine medicines because of the risk of serious serotonergic reactions. Official product information also warns against certain antifungal medicines such as ketoconazole and itraconazole because they can raise dapoxetine exposure.
Syncope, dizziness, and low blood pressure are recognised concerns, and the risk is more important in people with pre-existing fainting episodes or cardiovascular vulnerability. As with other SSRIs, caution is needed when there is a history of mood disorder, seizure disorder, or other medicines that affect serotonin or cardiac rhythm. The medicine is generally avoided in patients for whom the official product information lists contraindications or major interaction risks.
Possible Side Effects
Commonly reported adverse effects include nausea, dizziness, headache, somnolence, diarrhoea, and insomnia. Some people also report sweating, fatigue, or gastrointestinal discomfort. More serious reactions can include fainting, marked blood pressure changes, palpitations, and symptoms consistent with serotonin syndrome, such as agitation, tremor, fever, or confusion. Any severe or rapidly worsening reaction requires urgent medical attention.
Scientific Evidence
Human clinical studies and systematic reviews have found that dapoxetine improves intravaginal ejaculatory latency time and patient-reported control over ejaculation compared with placebo. Reviews also indicate that the 60 mg strength can provide greater efficacy than the 30 mg strength in some men, although adverse effects are also more frequent at the higher strength. Overall, the published evidence supports a real but modest benefit, balanced against a recognisable adverse-effect profile.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It is not a substitute for the official patient leaflet, the full prescribing information, or an individual assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA). Priligy (dapoxetine) referral overview and product information. View official source
- European Medicines Agency (EMA). Priligy 30 mg and 60 mg film-coated tablets, Annex III: Summary of Product Characteristics. View official source
- Jinhong Li et al. Dapoxetine for premature ejaculation: an updated meta-analysis of randomized controlled trials. Clinical Therapeutics, 2014. View scientific article
- A Russo et al. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. International Journal of Clinical Practice, 2016. View scientific article
